CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition.
Noeparast A, Giron P, Noor A, Bahadur Shahi R, De Brakeleer S, Eggermont C, Vandenplas H, Boeckx B, Lambrechts D, De Grève J, Teugels E.
Noeparast A, et al. Among authors: de brakeleer s, de greve j.
Oncogene. 2019 Aug;38(31):5933-5941. doi: 10.1038/s41388-019-0866-7. Epub 2019 Jul 8.
Oncogene. 2019.
PMID: 31285551
Free PMC article.